Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Bluejay Diagnostics (BJDX) Net Income towards Common Stockholders (2022 - 2023)

Bluejay Diagnostics' Net Income towards Common Stockholders history spans 2 years, with the latest figure at -$2.4 million for Q4 2023.

  • On a quarterly basis, Net Income towards Common Stockholders rose 2.73% to -$2.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$10.3 million, a 10.66% decrease, with the full-year FY2025 number at -$6.8 million, up 67.3% from a year prior.
  • Net Income towards Common Stockholders hit -$2.4 million in Q4 2023 for Bluejay Diagnostics, down from -$2.3 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for BJDX hit a ceiling of -$2.0 million in Q2 2022 and a floor of -$2.9 million in Q2 2023.